Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy
Publication date
2018-12-01
Authors
de Vries Schultink, Aurelia H.M.
Huitema, Alwin D.R.
Beijnen, Jos
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
Different strategies have been proposed to individualize tamoxifen treatment in order to improve recurrence-free survival in estrogen receptor (ER)-positive breast cancer. To date, the debate remains on which strategy should be used. The objective of this viewpoint is to highlight Therapeutic Drug Monitoring of endoxifen, the active tamoxifen metabolite, as the preferred methodology compared to CYP2D6 genotyping for individualizing tamoxifen therapy for ER-positive breast cancer patients treated in the adjuvant setting.
Keywords
Endoxifen, Therapeutic Drug Monitoring, Treatment individualization, Taverne, Surgery, SDG 3 - Good Health and Well-being
Citation
de Vries Schultink, A H M, Huitema, A D R & Beijnen, J H 2018, 'Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy', Breast, vol. 42, pp. 38-40. https://doi.org/10.1016/j.breast.2018.08.100